Compare CAPR & OBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | OBK |
|---|---|---|
| Founded | 2005 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2011 | 2018 |
| Metric | CAPR | OBK |
|---|---|---|
| Price | $28.78 | $40.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $44.63 | $44.29 |
| AVG Volume (30 Days) | ★ 1.2M | 122.3K |
| Earning Date | 03-12-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.40 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.43 |
| Revenue Next Year | $35.83 | $5.79 |
| P/E Ratio | ★ N/A | $17.12 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.30 | $28.80 |
| 52 Week High | $40.37 | $46.02 |
| Indicator | CAPR | OBK |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 41.73 |
| Support Level | $25.33 | $39.62 |
| Resistance Level | $30.06 | $46.02 |
| Average True Range (ATR) | 2.13 | 0.92 |
| MACD | -0.39 | 0.02 |
| Stochastic Oscillator | 7.67 | 27.73 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.